Taizhou Zecen Biotech Co.,Ltd.

Innovation For Health,Quality For Life

Manufacturer from China
Active Member
3 Years
Home / Products / IVD Products /

New Indicator For Liver Cancer Screening PIVKA-II IVD Products Tumor Maker Assay For Clinical In Vitro Diagnostic

Contact Now
Taizhou Zecen Biotech Co.,Ltd.
City:taizhou
Province/State:jiangsu
Contact Person:MrLiu
Contact Now

New Indicator For Liver Cancer Screening PIVKA-II IVD Products Tumor Maker Assay For Clinical In Vitro Diagnostic

Ask Latest Price
Video Channel
Brand Name :Zecen
Model Number :PIVKA-II
Certification :CE, ISO13485
Place of Origin :China
MOQ :10 boxes
Payment Terms :L/C, D/A, D/P, T/T, Western Union, MoneyGram
Supply Ability :5000 Set/Sets per Month
Delivery Time :15 working days
Packaging Details :Carton package
Name :PIVKA-II
Analyzer :CIA series
Principle :Enzymatic chemiluminescence
Luminescent markers :AP(alkaline phosphatase)
Calibrator :For Free
Storage :2-8°C
Material :Magnetic beads, calibrators, Anti A/B, controls
Validity period :18 months
Precision :≤8%
more
Contact Now

Add to Cart

Find Similar Videos
View Product Description

New indicator for liver cancer screening(PIVKA-II) test kit Tumor Maker Assay for Clinical In Vitro Diagnostic

Clinical Significance

In recent years, a large number of clinical studies have shown that PIVKA-II has good sensitivity and specificity, so PIVKA-IIP is gradually used as an indicator for liver cancer screening and diagnosis in clinical diagnosis.


Abnormal prothrombin increased, seen in more than 90% of hepatocellular carcinoma, the average can be as high as 900μg/L. APT elevation was also seen in 40% to 50% of metastatic liver cancers, but the mean value was lower.
In hepatocellular carcinoma with low alpha-fetoprotein (AFP) levels, APT tends to be elevated. It has been reported that for liver cancer with AFP lower than 400 μg/L, APT was higher than 300 μg/L in 57% of cases. Therefore, simultaneous detection of AFP and APT can improve the diagnosis rate of low-AFP HCC from 48% to 68%. In addition, mildly elevated APT is also seen in chronic hepatitis and vitamin K deficiency, which can be corrected with vitamin K supplementation at this time.

Prothrombin is the precursor of thrombin, and abnormal prothrombin refers to prothrombin synthesized by liver cells in the absence of vitamin K. The normal value of abnormal prothrombin should be less than 20μg/L. Abnormal prothrombin can be used as an indicator for judging hepatocellular carcinoma. When suffering from hepatocellular carcinoma, it will affect the generation of prothrombin precursor, resulting in a large amount of abnormal thrombin. Abnormal prothrombin, alpha-fetoprotein and other tests are commonly used in clinical practice, as well as pathological examinations to clarify the nature of the lesions.

CLIA Reagents of Tumor Maker(PIVKA-II)

Test Item PIVKA-II
Luminescent Principle Enzymatic chemiluminescence
Luminescent Markers AP(alkaline phosphatase)
Specification

100 Test/Kit for CIA series

Principle Sandwich method
Component Magnetic Beads
Calibrator Low
Calibrator High
Anti-A/Anti-B
Control 1
Control 2
Accessories Required But Not Provided Substrate
Washing solution
Sample material Serum/Plasma/Whole Blood
Storage 2-8℃

New Indicator For Liver Cancer Screening PIVKA-II IVD Products Tumor Maker Assay For Clinical In Vitro Diagnostic

New Indicator For Liver Cancer Screening PIVKA-II IVD Products Tumor Maker Assay For Clinical In Vitro Diagnostic

New Indicator For Liver Cancer Screening PIVKA-II IVD Products Tumor Maker Assay For Clinical In Vitro Diagnostic


Inquiry Cart 0